Get the Stockscreener App
54.51
2.04%
1.09
After Hours:
54.51
Viking Therapeutics Inc stock is traded at $54.51, with a volume of 2.57M.
It is up +2.04% in the last 24 hours and down -30.14% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$53.42
Open:
$53.33
24h Volume:
2.57M
Relative Volume:
0.63
Market Cap:
$5.97B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-58.61
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
+5.78%
1M Performance:
-30.14%
6M Performance:
-13.13%
1Y Performance:
+354.25%
1-Day Range:
$52.17
$54.73
1-Week Range:
$50.53
$56.25
52-Week Range:
$11.54
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
54.51 | 5.97B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.6%Time to Sell? - MarketBeat
Victory Capital Management Inc. Decreases Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 8.1%Should You Buy? - MarketBeat
Viking Therapeutics' (VKTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Massachusetts Financial Services Co. MA Has $15.72 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc.VKTX - PR Newswire
Viking Therapeutics (NASDAQ:VKTX) Trading Down 1.2%Here's Why - MarketBeat
Westfield Capital Management Co. LP Raises Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Brokers Offer Predictions for VKTX Q4 Earnings - MarketBeat
Viking Therapeutics is more than just a weight-loss stock, and that’s drawing cheers - MSN
Crewe Advisors LLC Invests $1.04 Million in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
B. Riley Upgrades Viking Therapeutics (NASDAQ:VKTX) to "Strong-Buy" - MarketBeat
3 Monster Stocks in the Making - The Motley Fool
B. Riley Securities Initiates Coverage of Viking Therapeutics (VKTX) with Buy Recommendation - MSN
Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735 - MSN
Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 0.9%Here's Why - MarketBeat
Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report? - MSN
Viking Therapeutics (NASDAQ:VKTX) Shares Gap UpHere's What Happened - MarketBeat
VKTX Stock Loses Over $1B in a Month: How to Play the Stock? - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Now Covered by Analysts at B. Riley - MarketBeat
B. Riley Securities initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Do Redditors Think That Viking Therapeutics Inc. (VKTX) Has a Big Upside Potential? - Insider Monkey
Viking Therapeutics (NASDAQ:VKTX) Shares Up 0.3%Here's What Happened - MarketBeat
11 Reddit Stocks with Biggest Upside Potential - Insider Monkey
13,334 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by Royce & Associates LP - MarketBeat
NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors - Citeline News & Insights
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - AOL
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.5%Here's What Happened - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Earns Outperform Rating from William Blair - MarketBeat
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 - The Malaysian Reserve
JW Asset Management LLC Acquires Shares of 45,000 Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data - MSN
Is It Too Late to Buy Viking Therapeutics Stock? - MSN
Viking phase 2b study of NASH candidate hits primary endpoint - Seeking Alpha
Viking Therapeutics' NASH Drug Shows 75% Disease Resolution in Phase 2b Trial | VKTX Stock News - StockTitan
Viking Therapeutics (NASDAQ:VKTX) Trading Down 1%Here's Why - MarketBeat
3 Things You Need to Know if You Buy Viking Therapeutics Today - AOL
Viking Therapeutics (NASDAQ:VKTX) Shares Down 1.4%Here's What Happened - MarketBeat
What the Options Market Tells Us About Viking Therapeutics - Benzinga
Viking Therapeutics Insiders Sold US$8.9m Of Shares Suggesting Hesitancy - Simply Wall St
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia) - AOL
LJI Wealth Management LLC Has $1.17 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On. - AOL
Viking Therapeutics (NASDAQ:VKTX) Shares Down 2.9%Should You Sell? - MarketBeat
Market Whales and Their Recent Bets on VKTX Options - Benzinga
Oppenheimer & Co. Inc. Has $6.48 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Aptus Capital Advisors LLC Purchases 9,699 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Sigma Planning Corp Acquires Shares of 15,119 Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand? - Yahoo! Voices
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):